These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 9923815

  • 1. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
    Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR, Dedrick RL.
    Cancer Chemother Pharmacol; 1999; 43(2):106-14. PubMed ID: 9923815
    [Abstract] [Full Text] [Related]

  • 2. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
    Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, Figg WD, Venzon DJ, Alexander HR.
    Cancer; 1998 Sep 15; 83(6):1251-61. PubMed ID: 9740093
    [Abstract] [Full Text] [Related]

  • 3. [The pharmacokinetics of intraperitoneal (IP) carboplatin (CBDCA) and dose-up study of intravenous (IV) cyclophosphamide (CPM) in combination with IP CBCDA for advanced ovarian cancer patients].
    Fujiwara K, Yamauchi H, Sawada S, Koike H, Mohri H, Ohishi Y, Kohno I.
    Gan To Kagaku Ryoho; 1992 Dec 15; 19(14):2373-9. PubMed ID: 1463344
    [Abstract] [Full Text] [Related]

  • 4. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma.
    Lentz SS, Miller BE, Kucera GL, Levine EA.
    Gynecol Oncol; 2007 Jul 15; 106(1):207-10. PubMed ID: 17498782
    [Abstract] [Full Text] [Related]

  • 5. Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacology.
    Formenti SC, Shrivastava PN, Sapozink M, Jozsef G, Chan KK, Jeffers S, Morrow PC, Muggia FM.
    Int J Radiat Oncol Biol Phys; 1996 Jul 15; 35(5):993-1001. PubMed ID: 8751408
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
    Los G, Smals OA, van Vugt MJ, van der Vlist M, den Engelse L, McVie JG, Pinedo HM.
    Cancer Res; 1992 Mar 01; 52(5):1252-8. PubMed ID: 1737387
    [Abstract] [Full Text] [Related]

  • 8. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB, Robinson BA.
    Clin Pharmacokinet; 1997 Sep 01; 33(3):161-83. PubMed ID: 9314610
    [Abstract] [Full Text] [Related]

  • 9. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.
    Ma GY, Bartlett DL, Reed E, Figg WD, Lush RM, Lee KB, Libutti SK, Alexander HR.
    Cancer J Sci Am; 1997 Sep 01; 3(3):174-9. PubMed ID: 9161783
    [Abstract] [Full Text] [Related]

  • 10. The retreatment of carboplatin via high-dose intraperitoneal chemotherapy in patients with a history of a hypersensitivity reaction.
    Rettenmaier MA, Gray CM, Lopez KL, Bechtol KA, Goldstein BH.
    Am J Obstet Gynecol; 2014 Feb 01; 210(2):e1-2. PubMed ID: 24184183
    [Abstract] [Full Text] [Related]

  • 11. A Bayesian dosing method for carboplatin given by continuous infusion for 120 h.
    Guillet P, Monjanel S, Nicoara A, Duffaud F, Lacarelle B, Bagarry-Liegey D, Durand A, Catalin J, Favre R.
    Cancer Chemother Pharmacol; 1997 Feb 01; 40(2):143-9. PubMed ID: 9182836
    [Abstract] [Full Text] [Related]

  • 12. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S, Huang H, Liao H, Zhan J, Guo Y, Zou BY, Jiang WQ, Guan ZZ, Yang XQ.
    Int J Clin Pharmacol Ther; 2013 Feb 01; 51(2):96-105. PubMed ID: 23127487
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis.
    Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, Lee KB, Venzon DJ, Bauer KS, Reed E, Figg WD.
    J Clin Pharmacol; 1999 Apr 01; 39(4):394-401. PubMed ID: 10197298
    [Abstract] [Full Text] [Related]

  • 14. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S, Ogasawara T, Ito K, Koyama M, Nagano T, Suzuki A, Yamada T, Nakata Y, Ozawa M.
    Oncol Rep; 2001 Apr 01; 8(2):285-8. PubMed ID: 11182041
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
    Morgan RJ, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5896-901. PubMed ID: 14676112
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
    Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH.
    Cancer Chemother Pharmacol; 2004 Oct 01; 54(4):283-9. PubMed ID: 15184995
    [Abstract] [Full Text] [Related]

  • 17. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
    Yamamoto R, Kaneuchi M, Nishiya M, Todo Y, Takeda M, Okamoto K, Negishi H, Sakuragi N, Fujimoto S, Hirano T.
    Cancer Chemother Pharmacol; 2002 Aug 01; 50(2):137-42. PubMed ID: 12172979
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients.
    Chambers SK, Chambers JT, Davis CA, Kohorn EI, Schwartz PE, Lorber MI, Handschumacher RE, Pizzorno G.
    J Clin Oncol; 1997 May 01; 15(5):1945-52. PubMed ID: 9164206
    [Abstract] [Full Text] [Related]

  • 19. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.
    van der Vange N, van Goethem AR, Zoetmulder FA, Kaag MM, van de Vaart PJ, ten Bokkel Huinink WW, Beijnen JH.
    Eur J Surg Oncol; 2000 Nov 01; 26(7):663-8. PubMed ID: 11078613
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
    Strauss HG, Henze A, Teichmann A, Karbe I, Baumgart A, Thomssen C, Koelbl H.
    Gynecol Oncol; 2007 Mar 01; 104(3):612-6. PubMed ID: 17069876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.